Title: INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: e14537
Title: INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: 431
Session Date/Time: 8:00 AM - 10:00 AM on Tuesday, May 11, 2021
Title: Intratumoral INTASYL™ self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody
Authors: Benjamin Cuiffo, et al.
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: 1739
Fireside Chat with Dr. Gerrit Dispersyn
Date: Thursday, December 3, 2020
Time: 3:05 p.m. EST
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Poster Title: Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer
Authors: Benjamin Cuiffo, et. al. Abstract Number: 198
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Presenter: Dr. Gerrit Dispersyn Date and Time: September 16, 2020 at 11:30 a.m. EST
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Abstract number: 5745 Title: Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment Session Title: Immune Checkpoints 2 Presenter: Dr. Simon P. Fricker
* This will be the second of two AACR virtual annual meeting events being held in 2020 due to the COVID-19 pandemic
